(OP:PMBHF)

N/A UNCHANGED

Last Price Updated: 9:46 AM EST, Jan 23, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about PMBHF

Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More ↗

January 15, 2024

Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.

Via Benzinga

Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More ↗

January 08, 2024

Welcome to Benzinga's weekly psychedelics news roundup. We have pulled together several must-read news items from the last week of December 2023 and the first of January 2024.

Via Benzinga

PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance

January 08, 2024

PharmAla to present its intellectual property assets to potential partners at the annual JPM healthcare conference on January 8-11th in San Francisco

From PharmAla Biotech

Via GlobeNewswire

Canada To Australia: New MDMA & Psilocybin Shipment On Its Way For Legal Therapeutic Market ↗

November 08, 2023

The first of several of PharmAla Biotech’s (OTC: PMBHF) shipments of psychedelic molecules -both API and finished drug product capsules- to its Australian JV Cortexa for use under the Authorized...

Via Benzinga

PharmAla Begins Trading on OTCQB

September 06, 2023

From PharmAla Biotech

Via GlobeNewswire

Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More ↗

August 14, 2023

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published

Via Benzinga

Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More ↗

August 03, 2023

A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...

Via Benzinga

PharmAla Files IP Protection For Novel MDXX Molecule: Viability As Autism Spectrum Treatment ↗

July 31, 2023

Canadian biotech company PharmAla Biotech Holdings (OTC: PMBHF) has filed a patent covering composition of matter of Novel Chemical Entity (NCE) PharmAla-1.

Via Benzinga

PharmAla Files Patent for Novel MDXX Molecule PharmAla-1

July 31, 2023

Patent Filing Follows Year of Preclinical Research, Academic Publication

From PharmAla Biotech

Via GlobeNewswire

Cybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical Trials ↗

July 24, 2023

Cybin One Steps Away From Complete Dosing

Via Benzinga

Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More ↗

July 11, 2023

First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic...

Via Benzinga

PharmAla's Australian JV Cortexa Orders First Commercial MDMA & Psilocybin Shipment ↗

July 05, 2023

As Australia’s psychedelic program launches, PharmAla Biotech Holdings Inc.’s (OTC: PMBHF) new

Via Benzinga

Life Science Investor Forum: Presentations Now Available for Online Viewing

June 23, 2023

Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Life Science Investor Forum Agenda Announced for June 22nd

June 20, 2023

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University ↗

June 20, 2023

Numinus Wellness (OTCMKTS: NUMIF) with support from the Multidisciplinary Association for Psychedelic Studies (MAPS) will utilize Optimi Health’s (OTCMKTS: OPTHF) Good Manufacturing Practice...

Via Benzinga

Canadian Financing: PharmAla Biotech Offers Non-Brokered Private Placement Up To $3.76M ↗

June 13, 2023

MDXX-class molecules biotech company PharmAla Biotech Holdings Inc. (OTCMKTS: PMBHF) has announced a non-brokered private placement of a minimum of 3.3 million units and a maximum of 16.6 million of...

Via Benzinga

Promising Milestone: FDA Approves California-Based Trial Assessing MDMA For Schizophrenia ↗

June 12, 2023

The FDA has approved a clinical trial that will assess PharmAla Biotech Holdings' (OTC: PMBHF) proprietary LaNeo Investigational Medical Product (IMP) 40mg MDMA capsules for the treatment of...

Via Benzinga

USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States

June 09, 2023

From PharmAla Biotech

Via GlobeNewswire

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.